Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2100052254Phase 4Recruiting
Phase 4, randomised trial of rivastigmine in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Xuanwu Hospital. Primary endpoint: AVLT score. Started Sep 2018; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2100052254.